Ken Griffin Annovis Bio, Inc. Transaction History
Citadel Advisors LLC
- $559 Billion
- Q4 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Annovis Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 15,000 shares of ANVS stock, worth $41,100. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15,000
Previous 17,800
15.73%
Holding current value
$41,100
Previous $143,000
47.55%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding ANVS
# of Institutions
48Shares Held
1.56MCall Options Held
348KPut Options Held
535K-
Vanguard Group Inc Valley Forge, PA466KShares$1.28 Million0.0% of portfolio
-
Black Rock Inc. New York, NY101KShares$275,9420.0% of portfolio
-
Geode Capital Management, LLC Boston, MA99.6KShares$272,8050.0% of portfolio
-
Merit Financial Group, LLC98.5KShares$269,9330.01% of portfolio
-
Jane Street Group, LLC New York, NY68.1KShares$186,6130.0% of portfolio
About Annovis Bio, Inc.
- Ticker ANVS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,163,920
- Market Cap $22.4M
- Description
- Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...